Hans van Eenennaam, Ph.D. has been promoted executive vice president antibody research and site head of Aduro Biotech Europe. In his new role, Dr. van Eenennaam will lead antibody research and oversee the company’s day to day operations.

Prior to its acquisition by Aduro in 2015, Dr. van Eenennaam served as chief operating officer of BioNovion, a company he co-founded in 2011 focused on the development of therapeutic antibodies in the field of immuno-oncology. Earlier in his career, he held numerous positions of increasing responsibility at Organon and the Organon Research Center in Cambridge, MA, which was acquired by Schering-Plough in 2007 and later by Merck. He led the discovery and development of therapeutic monoclonal antibodies and small molecule entities in the field of oncology and immunology.

“Hans continues to be an invaluable member of the Aduro team,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro Biotech, Inc. “Given Hans’ long history and expertise in the field of monoclonal antibodies, including inventorship of our anti-APRIL antibody, BION-1301, and the anti-CD27 antibody licensed to Merck, we look forward to Hans’ leadership in the discovery of novel antibody targets and their advancement through development.”